Anti-PD-1 antibody drug named Serplulimab
PALACE
Phase 3 small_molecule active
Quick answer
Anti-PD-1 antibody drug named Serplulimab for Locally Advanced Rectal Cancer (LARC) is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Locally Advanced Rectal Cancer (LARC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active